#3-91E. Reevaluating Oxygen Strategies: High-Flow vs Standard Therapy in Hypoxemic Failure (NEJM, 2026)

Does high-flow nasal cannula oxygen truly offer a definitive survival advantage over standard oxygen therapy for ICU patients with acute hypoxemic respiratory failure? In today’s episode, we explore a pivotal multicenter, open-label randomized clinical trial involving 1,110 patients that directly compared high-flow oxygen delivery against standard oxygen therapy, with a primary focus on assessing 28-day mortality. The trial’s most critical finding reveals that high-flow oxygen did not significantly reduce mortality at day 28, as both treatment groups demonstrated an identical 14.6% mortality rate, even though high-flow therapy showed some potential benefits in reducing intubation rates and rapidly alleviating patient dyspnea. However, when critically appraising this study, listeners must consider that the lower-than-expected overall mortality rate resulted in reduced statistical power, and the frequent concurrent use of glucocorticoids might have confounded the survival outcomes. For frontline clinicians, these insights are highly practical; they suggest that everyday oxygenation treatment decisions should no longer strictly anticipate a mortality benefit, but must pragmatically balance the risk of intubation, patient comfort, and the local availability of critical care resources.

Citation: Frat, J.-P., et al. High-Flow or Standard Oxygen in Acute Hypoxemic Respiratory Failure. New England Journal of Medicine. 2026. DOI: 10.1056/NEJMoa2516087

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.